Ophidion Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $1.1M

  • Investors
  • 9

Ophidion General Information

Description

Developer of gene-silencing therapies designed to treat neurodegenerative diseases following intravenous administration. The company's platform uses a trojan horse strategy to exploit an endogenous receptor-mediated transport system to deliver oligonucleotides and small interfering ribonucleic acids (siRNAs) following intravenous administration into the brain, enabling physicians to deliver therapeutics for the treatment of various central nervous system (CNS) disorders and brain malignancies.

Contact Information

Website
www.ophidion.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Pasadena Bioscience Collaborative
  • 2265 East Foothill Boulevard
  • Pasadena, CA 91107
  • United States
+1 (973)
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • Pasadena Bioscience Collaborative
  • 2265 East Foothill Boulevard
  • Pasadena, CA 91107
  • United States
+1 (973)

Ophidion Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ophidion Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 01-Oct-2024 $1.1M Completed Pre-Clinical Trials
4. Seed Round 26-Sep-2024 Completed Pre-Clinical Trials
3. Seed Round 24-May-2023 Completed Pre-Clinical Trials
2. Seed Round 14-Jan-2020 $1.7M $1.7M Completed Pre-Clinical Trials
1. Accelerator/Incubator Completed Pre-Clinical Trials
To view Ophidion’s complete valuation and funding history, request access »

Ophidion Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Seed
To view Ophidion’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Ophidion Patents

  • 27

    Total Documents Applications and Grants

  • Total Patents Families

  • 24

    Granted

  • 2

    Pending

  • Expiring in next 12 mo

Ophidion Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20200061155-A1 Compositions and methods for treating lynx2 disorders Inactive 11-May-2017
EP-3345627-B1 Compositions and methods for transport across the blood brain barrier Active 03-Jun-2011
EP-2714096-A1 Compositions and methods for transport across the blood brain barrier Active 03-Jun-2011
EP-2714096-B1 Compositions and methods for transport across the blood brain barrier Active 03-Jun-2011
US-9913915-B2 Compositions and methods for transport across the blood brain barrier Active 03-Jun-2011 A61K47/64
To view Ophidion’s complete patent history, request access »

Ophidion Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ophidion Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Eisai Corporate Venture Capital Minority
Eisai Innovation Corporate Venture Capital Minority
Ben Franklin Technology Partners of Northeastern Pennsylvania Venture Capital Minority
Delaware Crossing Investor Group Angel Group Minority
Gaingels Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

Ready to get started?

Request a free trial

Ophidion FAQs

  • When was Ophidion founded?

    Ophidion was founded in 2008.

  • Where is Ophidion headquartered?

    Ophidion is headquartered in Pasadena, CA.

  • What is the size of Ophidion?

    Ophidion has 8 total employees.

  • What industry is Ophidion in?

    Ophidion’s primary industry is Drug Discovery.

  • Is Ophidion a private or public company?

    Ophidion is a Private company.

  • What is Ophidion’s current revenue?

    The current revenue for Ophidion is .

  • How much funding has Ophidion raised over time?

    Ophidion has raised $4.41M.

  • Who are Ophidion’s investors?

    Eisai, Eisai Innovation, Ben Franklin Technology Partners of Northeastern Pennsylvania, Delaware Crossing Investor Group, and Gaingels are 5 of 9 investors who have invested in Ophidion.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »